Ginkgo Bioworks hauls in $275 mln Series D
Boston-based Ginkgo Bioworks, an organism company, has raised $275 million in Series D funding. The investors included Viking Global, Y Combinator's Continuity Fund, Cascade Investment and General Atlantic.
14 December 2017•1 min read
